Skip to main content

Table 5 Statistical parameters characterizing the results obtained from Kaplan-Meier survival curves for PD. Characterization of Parkinson's Disease Incidence in the Statin Groups and CV Comparator

From: Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease

   Dementia cases Time to incidence for dementia cases (months) Time to end of study for non-dementia cases (months)  
Drug Sample size (n) n % Mean SD Mean SD Model 3: HR for incidence of dementia vs CV (95% CI)
CV 392 966 2417 0.62 19.5 8.0 30.3 8.6  
Atorvastatin 53 701 224 0.42 17.9 7.7 24.0 11.5 0.99 (0.86–1.14)
Lovastatin 53 711 350 0.65 18.8 7.9 29.7 8.1 1.09 (0.98–1.22)
Simvastatin 725 820 2116 0.29 19.3 7.9 29.1 8.0 0.51 (0.49–0.55)
  1. Column 1, medication group; column 2, sample size; column 3, number of dementia cases recorded during the course of the analytic period; column 4, percentage of PD cases (calculated by dividing the value in column 3 by that in column 2); columns 5 and 6, number of months between start of the analytic period and incidence of dementia, and standard deviation (SD); columns 7 and 8, number of months between start of the analytic period and point at which subjects not receiving a diagnosis of PD were censored due to the end of the analytic period, and SD.
  2. Hazard ratio for incidence of PD based on the results from model 3 (Table 4).